Fundraising Fox

Seres Therapeutics

NASDAQ: MCRB

Cambridge, US · Founded 2010 · 109 employees on LinkedIn · 4 known investors

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

MHMatthew Henn
Matthew HenninPresident and Chief Scientific Officer
JA
John AuninsExecutive
ED
Eric D. ShaffExecutive
DC
David CookExecutive
RJ
Roger J. PomerantzExecutive

Board

DBDavid Berry
David Berryin𝕏Board directorGeneral Partner at Flagship Pioneering
NANoubar Afeyan
Noubar Afeyanin𝕏Co-Founder and Board Member2011–2020Investor at Flagship Pioneering
GB
Greg BeharBoard director
PB
Peter Barton HuttBoard director
RK
Richard KenderBoard director
WC
Werner CautreelsBoard director
LK
Lorence KimBoard director

Investors · 4

Flagship Pioneering✓ verifiedCambridge · $500K – $10M
RA CapitalBoston
Sofinnova VenturesMenlo Park · $100K – $15M
Fidelity InvestmentsreportedBoston

Reported raises · per SEC filings

Form D private placements

$123.6M disclosed across 3 of 7 rounds · 1900–2014

▶$65MraisedJan 2015 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter Barton HuttDirector
  • Richard KenderDirector
  • David BerryDirector
  • Werner CautreelsDirector
  • Noubar AfeyanDirector
  • John AuninsExecutive Officer
  • Eric D. ShaffExecutive Officer
  • David CookExecutive Officer
  • Lorence KimDirector
  • Greg BeharDirector
  • Roger J. PomerantzExecutive Officer, Director
Offering amount
$65M
Amount sold
$65M
First sale
Dec 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$48MraisedDec 2014 · 20 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David BerryDirector
  • Richard KenderDirector
  • Werner CautreelsDirector
  • Roger J. PomerantzExecutive Officer, Director
  • John AuninsExecutive Officer
  • Eric D. ShaffExecutive Officer
  • Lorence KimDirector
  • Noubar AfeyanDirector
  • Peter Barton HuttDirector
  • David CookExecutive Officer
Offering amount
$48M
Amount sold
$48M
First sale
Nov 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.6MraisedJun 2014 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Werner CautreelsDirector
  • David BerryDirector
  • Noubar AfeyanDirector
  • Roger PomerantzExecutive Officer, Director
  • Peter Barton HuttDirector
Offering amount
$10.6M
Amount sold
$10.6M
First sale
May 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$547.3Mvaluation at IPOJun 2015 · $18.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Seres Therapeutics went on to found or lead other companies.

Noubar AfeyanCo-Founder and Board MemberFounded ProFound Therapeutics +12Geoffrey von MaltzahnCo-Founder, CTO (2010-2012)Founded Sienna Biopharmaceuticals +4

Competitors · 2

by search overlap
Robinhood25 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Sarepta Therapeutics24 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.

Companies competing with Seres Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Seres Health Announces $65 Million Investment from Nestle Health Scienceprnewswire.com · Jan 2015Seres Health Closes $48 Million Series C Financing | Fierce Biotechfiercebiotech.com · Dec 2014

Frequently asked questions

What does Seres Therapeutics do?
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.
Who are Seres Therapeutics's investors?
Seres Therapeutics's investors include Flagship Pioneering, RA Capital, Sofinnova Ventures, Fidelity Investments.
How much funding has Seres Therapeutics raised?
Seres Therapeutics has disclosed $123.6M raised across 3 of its 7 known rounds.
Where is Seres Therapeutics headquartered?
Seres Therapeutics is headquartered in Cambridge, US.